Chongqing Genrix Biopharmaceutical688443.SHValuation Analysis

As of Oct 19, 2026, Chongqing Genrix Biopharmaceutical (688443.SH) trades at a negative P/E (-14.99x, due to a recent net loss), P/B of 6.60x, P/S of 27.50x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 84th percentile over the trailing 10Y window (vs. 82nd percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 4th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 92nd percentile within its industry and the 88th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.07%, ranking at the 65th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Chongqing Genrix Biopharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.